<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03538301</url>
  </required_header>
  <id_info>
    <org_study_id>ND-L02-s0201-005</org_study_id>
    <nct_id>NCT03538301</nct_id>
  </id_info>
  <brief_title>JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nitto Denko Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nitto Denko Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the
      safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for
      Injection in subjects with IPF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>Change in the incidence and severity of adverse events related to study treatment from baseline to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the biological activity of ND-L02-s0201 as measured by spirometry</measure>
    <time_frame>Baseline vs. 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate changes of interstitial lung abnormalities as measured by HRCT</measure>
    <time_frame>Baseline vs. 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate maximum plasma concentration (Cmax)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to maximum plasma concentration (Tmax)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate area under the first moment of the plasma concentration-time curve (AUMC)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate total plasma clearance of drug (CL)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate apparent terminal elimination rate constant (Kel)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate volume of distribution at steady state (Vss)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate volume of distribution during the elimination phase (Vz)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate apparent terminal elimination half-life (T1/2)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate trough plasma concentration (Ctrough)</measure>
    <time_frame>Over 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>ND-L02-s0201 (Dose Level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 (Dose Level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND-L02-s0201</intervention_name>
    <description>Intravenous administration every 2 weeks</description>
    <arm_group_label>ND-L02-s0201 (Dose Level 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND-L02-s0201</intervention_name>
    <description>Intravenous administration every 2 weeks</description>
    <arm_group_label>ND-L02-s0201 (Dose Level 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Other: Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Forced vital capacity (FVC) ≥ 45% of predicted.

          -  Diffusion capacity of the lung for carbon monoxide (DLco) corrected for hemoglobin ≥
             30% of predicted value

          -  Ratio of forced expiratory volume in 1 second (FEV1) to FVC ≥ 0.70.

        Exclusion Criteria:

          -  Best, acceptable FVC from separate screening spirometry that differ by ≥ 200 mL.

          -  Respiratory exacerbation(s) or hospitalization for IPF exacerbation within 3 months
             before screening.

          -  Anticipated to receive a lung transplant during the subject's participation in the
             study.

          -  Active smoker or smoking cessation within 12 weeks before screening.

          -  Malignancy within the last 5 years, with the exception of curable cancer that has
             received adequate treatment.

          -  Evidence of any unstable or untreated, clinically significant disease or condition
             that, in the opinion of the Investigator, might confound the interpretation of the
             study or place the subject at increased risk.

          -  Treatment with high dose corticosteroids, cytotoxic agents, unapproved IPF targeted
             therapy, and cytokine modulating agents within 8 weeks or 5 half-lives (whichever is
             longer) before screening

          -  Participation in an investigational study with the last dose of investigational
             product occurring within 8 weeks or 5 half-lives (whichever is longer) before
             screening.

          -  Pregnant or breastfeeding.

          -  Medical history of infection with HIV, hepatitis B, or hepatitis C.

          -  History of alcohol abuse and/or dependence within the last 2 years.

          -  History within the last 2 years of significant mental illness, or physical dependence
             on any opioid or illicit drugs.

        Other protocol defined inclusion/exclusion criteria could apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitto Denko Corporation</last_name>
    <role>Study Director</role>
    <affiliation>Nitto Denko Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Contact recruiting sites directly for detail information. If there is no contact listed;</last_name>
    <phone>+81-3-6632-2069</phone>
    <email>nitto-005-study@rrdintl.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Jackman</last_name>
      <phone>310-423-4765</phone>
      <email>Susan.Jackman@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Niree Hindoyan</last_name>
      <phone>310-423-3598</phone>
      <email>Niree.Hindoyan@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Falk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco, Medical Center at Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reed Norris</last_name>
      <phone>415-476-7054</phone>
      <email>Reed.Norris@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Genevieve Montas</last_name>
      <phone>415-476-5034</phone>
      <email>genevieve.montas@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Golden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torsak Vimoktayon</last_name>
      <phone>904-953-3238</phone>
      <email>Vimoktayon.Torsak@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Tarik Haddad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Foust</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>135</phone_ext>
      <email>sfoust@cfpulmonary.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Summo</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>225</phone_ext>
      <email>ksummo@cfpulmonary.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Haim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Halaby</last_name>
      <phone>404-712-7458</phone>
      <email>tracy.halaby@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Srihari Veeraraghavan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josefina Corral</last_name>
      <phone>708-216-5744</phone>
      <email>jcorral@luc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Filip Wilk</last_name>
      <phone>708-216-2028</phone>
      <email>fwilk@luc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Dilling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Saint Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61606-2035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Bolliger</last_name>
      <phone>309-655-4727</phone>
      <email>Dawn.R.Bolliger@osfhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Hartwig</last_name>
      <phone>309-655-4229</phone>
      <email>Kimberly.Hartwig@osfhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Dunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Clinical Research Group</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy McDonald</last_name>
      <phone>502-479-1217</phone>
      <phone_ext>134</phone_ext>
      <email>nancy.mcdonald@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>David Winslow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Layla Rahimi</last_name>
      <phone>617-724-5548</phone>
      <email>layla.rahimi@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mamary Kone</last_name>
      <phone>617-726-1082</phone>
      <email>mkone@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leo Ginns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Wong</last_name>
      <phone>617-525-7654</phone>
      <email>ywong6@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Swati Gulati</last_name>
      <phone>617-732-8256</phone>
      <email>sgulati@bwh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Hunninghake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Medical School</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommy Goodwin</last_name>
      <phone>612-625-7719</phone>
      <email>goodw020@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Hyun Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center (DHMC)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Dickie</last_name>
      <phone>603-650-4711</phone>
      <email>kathy.a.dickie@hitchcock.edu</email>
    </contact>
    <contact_backup>
      <last_name>Polly Folsom</last_name>
      <phone>603-650-4711</phone>
      <email>Polly.M.Folsom@hitchcock.org</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Enelow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Tilley</last_name>
      <phone>919-668-8854</phone>
      <email>shannon.tilley@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Lake Morrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Griffiths</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>284024</phone_ext>
      <email>dgriffiths@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Bascom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Myers</last_name>
      <phone>412-692-2149</phone>
      <email>myersma@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Macpherson</last_name>
      <phone>412-647-4537</phone>
      <email>macphersonmj@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kevin Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Rasberry</last_name>
      <phone>843-792-2375</phone>
      <email>rasberry@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Chamberlain</last_name>
      <phone>843-792-3162</phone>
      <email>chambeam@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>J.Terrill Huggins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhoda Annoh Gordon</last_name>
      <phone>214-645-7108</phone>
      <email>Rhoda.AnnohGordon@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Balaji Kolasani</last_name>
      <email>balaki.kolasani@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Corey Kershaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health San Antonio: First Outpatient Research Unit</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilda Pomroy</last_name>
      <phone>210-450-9022</phone>
      <email>pomroy@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Polanco</last_name>
      <email>polancoj@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anoop Nambiar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Martinez</last_name>
      <phone>801-213-2650</phone>
      <email>Joseph.Martinez@utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Scott Sweeten</last_name>
      <phone>801-581-5811</phone>
      <email>Scott.Sweeten@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Beth Scholand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lungenfachklinik Immenhausen</name>
      <address>
        <city>Immenhausen</city>
        <state>Hesse</state>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrin Schwedler</last_name>
      <phone>+49(0) 5673 501 448</phone>
      <email>k.schwedler@lungenfachklinik-immenhausen.de</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Vorreiter</last_name>
      <phone>+49(0) 5673 501 153</phone>
      <email>nvorreiter@lungenfachklinik-immenhausen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Hammerl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <state>Lower Saxony</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Tayler</last_name>
      <phone>+49 511 532 3548</phone>
      <email>tayler.susanne@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Franziska Zetzche</last_name>
      <email>zetzsche.franziska@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Antje Prasse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitatsklinkum Essen gGmbH</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>NRW 45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Kilicaslan</last_name>
      <phone>0049 201 4334601</phone>
      <email>christina.kilicaslan@rik.uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Francesco Bonella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik-Heidelberg gGmbH</name>
      <address>
        <city>Heidelberg</city>
        <state>North Rhine-Westphalia</state>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Mueller</last_name>
      <phone>+49 (0) 6221 396 8209</phone>
      <email>lisa1.mueller@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Dagmar Altner</last_name>
      <phone>+49 (0) 6221 396 8214</phone>
      <email>Dagmar.altner@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Kreuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Himeji Medical Center</name>
      <address>
        <city>Himeji-Shi</city>
        <state>Hyogo</state>
        <zip>670-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tetsuji Kawamura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Takashi Ogura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital Oganization Kinki-chuo Chest Medical Center</name>
      <address>
        <city>Osaka</city>
        <state>Sakai-shi</state>
        <zip>5918555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoshikazu Inoue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Aichi</city>
        <state>Seto-shi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yasuhiro Kondoh, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kane Dorey</last_name>
      <phone>+44 1223 639823</phone>
      <email>kanedorey@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Juan Carlos Quijano-Campos</last_name>
      <email>juancarlos.quijano-campos@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Helen Parfrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Nicol</last_name>
      <phone>01158231474</phone>
      <email>Rebecca.Nicol2@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Norma Thompson</last_name>
      <phone>44(0)115 82 31315</phone>
      <email>Norma.Thompson@nottingham.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Gauri Saini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Medicines Evaluation Unit (MEU) Ltd.</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Pearson</last_name>
      <phone>44 0161 946 4059</phone>
      <email>SPearson@meu.org.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jon Goddard</last_name>
      <email>JGoddard@meu.org.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nazia Chaudhuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2018</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

